| Species |
Human |
| Protein Construction |
| His |
ANGPTL4/Angiopoietin-like 4 (Pro166-Ser406)
Accession # Q9BY76-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Human LILRB2, hFc Tag captured on CM5 Chip via Protein A can bind ANGPTL4/Angiopoietin-like 4, His, Human in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
28.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-40 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Candidates for this common regulatory system include signals mediated by peroxisome proliferator-activated regulator and its response factor, angiopoietin-like 4. The expression and bioactivity of angiopoietin-like 4, an adipocytokine that was originally reported to have an angiogenic function, have been detected not only in the vascular system and adipose tissue but also in rheumatoid joints. |
| Synonyms |
ANGPTL4; ARP4; FIAF; HFARP; Angiopoietin like 4; NGPTL2; NL2; PGAR; pp1158; ANG-3; ANG4; AGP4; ANG3; ANG-3; ANG-4; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
